Oncopeptides AB (publ)

Oncopeptides AB (publ) is a Swedish biotech company specializing in the research, development, and commercialization of targeted therapies for difficult-to-treat cancers, particularly hematological malignancies like multiple myeloma. Founded in 2000 by leading Swedish cancer researchers, the company is headquartered in Stockholm with around 75 employees and a pre-clinical facility in Solna. Its flagship product, Pepaxti (melflufen), a Peptide Drug Conjugate (PDC) based on proprietary technology, received full marketing authorization in Europe for adult patients with triple-class refractory multiple myeloma in combination with dexamethasone. This innovative alkylating agent offers robust efficacy while aiming to reduce treatment burden and preserve quality of life. Oncopeptides maintains a robust pipeline featuring additional PDC candidates and the Small Polypeptide based Killer Engagers (SPiKE) platform, addressing significant unmet needs in oncology. Guided by core values of science, passion, collaboration, courage, and trust, the company fosters an inclusive, entrepreneurial culture committed to advancing patient outcomes through data-driven innovation and global commercialization efforts, primarily in Europe.